CHMP Backs Galcanezumab for Migraine Prevention

The EMA committee has recommended marketing authorization for a second CGRP antagonist for migraine prevention, following its first-in-class approval recommendation for erenumab in May.
Medscape Medical News

Source link

Related posts

Patient hand and artistic depiction of chronic inflammatory demyelinating polyradiculoneuropathy


Brain Computer Interface Enables People with Paralysis to Control Tablets


What's happening in Neurology


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy